This is how you can introduce your patient to GLP-1 therapy, integrating it thoughtfully into a comprehensive weight management plan for safe and sustainable results
#Research #Type2Diabetes #CardiovascularDisease #MicroRNA #SIRT1 #PrecisionMedicine #MolecularBiology #Biomarkers #TranslationalMedicine #MedicalGenomics #DiabetesResearch #CardiovascularResearch #UFJ #Science #OpenAccess To view or add a comment, sign in This is a historic moment for RNA therapeutics, and I could not be prouder of the Ractigen team
According to FDA guidance, the FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed
Sermorelin + GHK-Cu Stack: Evidence, Mechanism, and Protocol At a glance Sermorelin class / GHRH 1-29 analog, stimulates pituitary GH release GHK-Cu class / copper-binding tripeptide (Gly-His-Lys-Cu) Primary sermorelin target / pituitary somatotrophs via GHRH receptor Primary GHK-Cu target / fibroblasts, macrophages, endothelial cells Highest-quality sermorelin evidence / placebo-controlled trial by Vittone et al
Image Credit: khomkrit sangkatechon / Shutterstock A recent study published in The Journal of Clinical Endocrinology & Metabolism showed that retatrutide treatment altered metabolites associated with insulin resistance and fatty acid oxidation (FAO) among people with obesity with or without type 2 diabetes (T2D)
1 2 "Myopathies associated with thyroid disease"